 | • レポートコード：MRC2-11QY00280 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はCINV既存・パイプライン治療薬のグローバル市場について調査・分析したレポートです。種類別（アロキシ（パロノセトロン）、ゾフランジェネリック（オンダンセトロン）、キトリルジェネリック（グラニセトロン）、エメンド（アプレピタント）、アキンゼオ（ネツピタント-パロノセトロン）、SUSTOL（徐放性グラニセトロン注射）、ロラピタント）市場規模、用途別（病院、専門クリニック、診断センター治療、病院薬局、ドラッグストア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別CINV既存・パイプライン治療薬の競争状況、市場シェア ・世界のCINV既存・パイプライン治療薬市場：種類別市場規模 2015年-2020年（アロキシ（パロノセトロン）、ゾフランジェネリック（オンダンセトロン）、キトリルジェネリック（グラニセトロン）、エメンド（アプレピタント）、アキンゼオ（ネツピタント-パロノセトロン）、SUSTOL（徐放性グラニセトロン注射）、ロラピタント） ・世界のCINV既存・パイプライン治療薬市場：種類別市場規模予測 2021年-2026年（アロキシ（パロノセトロン）、ゾフランジェネリック（オンダンセトロン）、キトリルジェネリック（グラニセトロン）、エメンド（アプレピタント）、アキンゼオ（ネツピタント-パロノセトロン）、SUSTOL（徐放性グラニセトロン注射）、ロラピタント） ・世界のCINV既存・パイプライン治療薬市場：用途別市場規模 2015年-2020年（病院、専門クリニック、診断センター治療、病院薬局、ドラッグストア） ・世界のCINV既存・パイプライン治療薬市場：用途別市場規模予測 2021年-2026年（病院、専門クリニック、診断センター治療、病院薬局、ドラッグストア） ・北米のCINV既存・パイプライン治療薬市場分析：米国、カナダ ・ヨーロッパのCINV既存・パイプライン治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのCINV既存・パイプライン治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のCINV既存・パイプライン治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのCINV既存・パイプライン治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：GlaxoSmithKline、Helsinn、Heron Therapeutics、Merck、Tesaro ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
Market Analysis and Insights: Global CINV Existing and Pipeline Drugs Market
The global CINV Existing and Pipeline Drugs market size is projected to reach US$ 1565.2 million by 2026, from US$ 1512.4 million in 2020, at a CAGR of 3.2%% during 2021-2026.
Global CINV Existing and Pipeline Drugs Scope and Market Size
CINV Existing and Pipeline Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global CINV Existing and Pipeline Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the CINV Existing and Pipeline Drugs market is segmented into
Aloxi (palonosetron)
Zofran Generic (ondansetron)
Kytril Generic (granisetron)
Emend (aprepitant)
Akynzeo (netupitant-palonosetron)
SUSTOL (extended release granisetron injection)
Rolapitant
Segment by Application, the CINV Existing and Pipeline Drugs market is segmented into
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Regional and Country-level Analysis
The CINV Existing and Pipeline Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the CINV Existing and Pipeline Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and CINV Existing and Pipeline Drugs Market Share Analysis
CINV Existing and Pipeline Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in CINV Existing and Pipeline Drugs business, the date to enter into the CINV Existing and Pipeline Drugs market, CINV Existing and Pipeline Drugs product introduction, recent developments, etc.
The major vendors covered:
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
…
1 Study Coverage
1.1 CINV Existing and Pipeline Drugs Product Introduction
1.2 Market Segments
1.3 Key CINV Existing and Pipeline Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Type
1.4.2 Aloxi (palonosetron)
1.4.3 Zofran Generic (ondansetron)
1.4.4 Kytril Generic (granisetron)
1.4.5 Emend (aprepitant)
1.4.6 Akynzeo (netupitant-palonosetron)
1.4.7 SUSTOL (extended release granisetron injection)
1.4.8 Rolapitant
1.5 Market by Application
1.5.1 Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Specialty Clinics
1.5.4 Diagnostic Centers Therapeutics
1.5.5 Hospital Pharmacies
1.5.6 Drugstores
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global CINV Existing and Pipeline Drugs Market Size, Estimates and Forecasts
2.1.1 Global CINV Existing and Pipeline Drugs Revenue 2015-2026
2.1.2 Global CINV Existing and Pipeline Drugs Sales 2015-2026
2.2 Global CINV Existing and Pipeline Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global CINV Existing and Pipeline Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global CINV Existing and Pipeline Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global CINV Existing and Pipeline Drugs Competitor Landscape by Players
3.1 CINV Existing and Pipeline Drugs Sales by Manufacturers
3.1.1 CINV Existing and Pipeline Drugs Sales by Manufacturers (2015-2020)
3.1.2 CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 CINV Existing and Pipeline Drugs Revenue by Manufacturers
3.2.1 CINV Existing and Pipeline Drugs Revenue by Manufacturers (2015-2020)
3.2.2 CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global CINV Existing and Pipeline Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by CINV Existing and Pipeline Drugs Revenue in 2019
3.2.5 Global CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 CINV Existing and Pipeline Drugs Price by Manufacturers
3.4 CINV Existing and Pipeline Drugs Manufacturing Base Distribution, Product Types
3.4.1 CINV Existing and Pipeline Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers CINV Existing and Pipeline Drugs Product Type
3.4.3 Date of International Manufacturers Enter into CINV Existing and Pipeline Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global CINV Existing and Pipeline Drugs Market Size by Type (2015-2020)
4.1.1 Global CINV Existing and Pipeline Drugs Sales by Type (2015-2020)
4.1.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2015-2020)
4.1.3 CINV Existing and Pipeline Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global CINV Existing and Pipeline Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Type (2021-2026)
4.2.3 CINV Existing and Pipeline Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global CINV Existing and Pipeline Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global CINV Existing and Pipeline Drugs Market Size by Application (2015-2020)
5.1.1 Global CINV Existing and Pipeline Drugs Sales by Application (2015-2020)
5.1.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2015-2020)
5.1.3 CINV Existing and Pipeline Drugs Price by Application (2015-2020)
5.2 CINV Existing and Pipeline Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global CINV Existing and Pipeline Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America CINV Existing and Pipeline Drugs by Country
6.1.1 North America CINV Existing and Pipeline Drugs Sales by Country
6.1.2 North America CINV Existing and Pipeline Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America CINV Existing and Pipeline Drugs Market Facts & Figures by Type
6.3 North America CINV Existing and Pipeline Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe CINV Existing and Pipeline Drugs by Country
7.1.1 Europe CINV Existing and Pipeline Drugs Sales by Country
7.1.2 Europe CINV Existing and Pipeline Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe CINV Existing and Pipeline Drugs Market Facts & Figures by Type
7.3 Europe CINV Existing and Pipeline Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific CINV Existing and Pipeline Drugs by Region
8.1.1 Asia Pacific CINV Existing and Pipeline Drugs Sales by Region
8.1.2 Asia Pacific CINV Existing and Pipeline Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific CINV Existing and Pipeline Drugs Market Facts & Figures by Type
8.3 Asia Pacific CINV Existing and Pipeline Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America CINV Existing and Pipeline Drugs by Country
9.1.1 Latin America CINV Existing and Pipeline Drugs Sales by Country
9.1.2 Latin America CINV Existing and Pipeline Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America CINV Existing and Pipeline Drugs Market Facts & Figures by Type
9.3 Central & South America CINV Existing and Pipeline Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa CINV Existing and Pipeline Drugs by Country
10.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country
10.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa CINV Existing and Pipeline Drugs Market Facts & Figures by Type
10.3 Middle East and Africa CINV Existing and Pipeline Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Corporation Information
11.1.2 GlaxoSmithKline Description and Business Overview
11.1.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products Offered
11.1.5 GlaxoSmithKline Related Developments
11.2 Helsinn
11.2.1 Helsinn Corporation Information
11.2.2 Helsinn Description and Business Overview
11.2.3 Helsinn Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Helsinn CINV Existing and Pipeline Drugs Products Offered
11.2.5 Helsinn Related Developments
11.3 Heron Therapeutics
11.3.1 Heron Therapeutics Corporation Information
11.3.2 Heron Therapeutics Description and Business Overview
11.3.3 Heron Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Products Offered
11.3.5 Heron Therapeutics Related Developments
11.4 Merck
11.4.1 Merck Corporation Information
11.4.2 Merck Description and Business Overview
11.4.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Merck CINV Existing and Pipeline Drugs Products Offered
11.4.5 Merck Related Developments
11.5 Tesaro
11.5.1 Tesaro Corporation Information
11.5.2 Tesaro Description and Business Overview
11.5.3 Tesaro Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Tesaro CINV Existing and Pipeline Drugs Products Offered
11.5.5 Tesaro Related Developments
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Corporation Information
11.1.2 GlaxoSmithKline Description and Business Overview
11.1.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products Offered
11.1.5 GlaxoSmithKline Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 CINV Existing and Pipeline Drugs Market Estimates and Projections by Region
12.1.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global CINV Existing and Pipeline Drugs Revenue Forecast by Regions 2021-2026
12.2 North America CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
12.2.1 North America: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
12.2.2 North America: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
12.2.3 North America: CINV Existing and Pipeline Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
12.3.2 Europe: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: CINV Existing and Pipeline Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: CINV Existing and Pipeline Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: CINV Existing and Pipeline Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa CINV Existing and Pipeline Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: CINV Existing and Pipeline Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: CINV Existing and Pipeline Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: CINV Existing and Pipeline Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key CINV Existing and Pipeline Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 CINV Existing and Pipeline Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. CINV Existing and Pipeline Drugs Market Segments
Table 2. Ranking of Global Top CINV Existing and Pipeline Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Type 2020-2026 (Kg) & (US$ Million)
Table 4. Major Manufacturers of Aloxi (palonosetron)
Table 5. Major Manufacturers of Zofran Generic (ondansetron)
Table 6. Major Manufacturers of Kytril Generic (granisetron)
Table 7. Major Manufacturers of Emend (aprepitant)
Table 8. Major Manufacturers of Akynzeo (netupitant-palonosetron)
Table 9. Major Manufacturers of SUSTOL (extended release granisetron injection)
Table 10. Major Manufacturers of Rolapitant
Table 11. Global CINV Existing and Pipeline Drugs Market Size Growth Rate by Application 2020-2026 (Kg)
Table 12. Global CINV Existing and Pipeline Drugs Market Size by Region (Kg) & (US$ Million): 2020 VS 2026
Table 13. Global CINV Existing and Pipeline Drugs Sales by Regions 2015-2020 (Kg)
Table 14. Global CINV Existing and Pipeline Drugs Sales Market Share by Regions (2015-2020)
Table 15. Global CINV Existing and Pipeline Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global CINV Existing and Pipeline Drugs Sales by Manufacturers (2015-2020) (Kg)
Table 17. Global CINV Existing and Pipeline Drugs Sales Share by Manufacturers (2015-2020)
Table 18. Global CINV Existing and Pipeline Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global CINV Existing and Pipeline Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CINV Existing and Pipeline Drugs as of 2019)
Table 20. CINV Existing and Pipeline Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers CINV Existing and Pipeline Drugs Price (2015-2020) (USD/Kg)
Table 23. CINV Existing and Pipeline Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers CINV Existing and Pipeline Drugs Product Type
Table 25. Date of International Manufacturers Enter into CINV Existing and Pipeline Drugs Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global CINV Existing and Pipeline Drugs Sales by Type (2015-2020) (Kg)
Table 28. Global CINV Existing and Pipeline Drugs Sales Share by Type (2015-2020)
Table 29. Global CINV Existing and Pipeline Drugs Revenue by Type (2015-2020) (US$ Million)
Table 30. Global CINV Existing and Pipeline Drugs Revenue Share by Type (2015-2020)
Table 31. CINV Existing and Pipeline Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Kg)
Table 32. Global CINV Existing and Pipeline Drugs Sales by Application (2015-2020) (Kg)
Table 33. Global CINV Existing and Pipeline Drugs Sales Share by Application (2015-2020)
Table 34. North America CINV Existing and Pipeline Drugs Sales by Country (2015-2020) (Kg)
Table 35. North America CINV Existing and Pipeline Drugs Sales Market Share by Country (2015-2020)
Table 36. North America CINV Existing and Pipeline Drugs Revenue by Country (2015-2020) (US$ Million)
Table 37. North America CINV Existing and Pipeline Drugs Revenue Market Share by Country (2015-2020)
Table 38. North America CINV Existing and Pipeline Drugs Sales by Type (2015-2020) (Kg)
Table 39. North America CINV Existing and Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 40. North America CINV Existing and Pipeline Drugs Sales by Application (2015-2020) (Kg)
Table 41. North America CINV Existing and Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 42. Europe CINV Existing and Pipeline Drugs Sales by Country (2015-2020) (Kg)
Table 43. Europe CINV Existing and Pipeline Drugs Sales Market Share by Country (2015-2020)
Table 44. Europe CINV Existing and Pipeline Drugs Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Country (2015-2020)
Table 46. Europe CINV Existing and Pipeline Drugs Sales by Type (2015-2020) (Kg)
Table 47. Europe CINV Existing and Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 48. Europe CINV Existing and Pipeline Drugs Sales by Application (2015-2020) (Kg)
Table 49. Europe CINV Existing and Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific CINV Existing and Pipeline Drugs Sales by Region (2015-2020) (Kg)
Table 51. Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific CINV Existing and Pipeline Drugs Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific CINV Existing and Pipeline Drugs Sales by Type (2015-2020) (Kg)
Table 55. Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific CINV Existing and Pipeline Drugs Sales by Application (2015-2020) (Kg)
Table 57. Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 58. Latin America CINV Existing and Pipeline Drugs Sales by Country (2015-2020) (Kg)
Table 59. Latin America CINV Existing and Pipeline Drugs Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa CINV Existing and Pipeline Drugs Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America CINV Existing and Pipeline Drugs Revenue Market Share by Country (2015-2020)
Table 62. Latin America CINV Existing and Pipeline Drugs Sales by Type (2015-2020) (Kg)
Table 63. Latin America CINV Existing and Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 64. Latin America CINV Existing and Pipeline Drugs Sales by Application (2015-2020) (Kg)
Table 65. Latin America CINV Existing and Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2015-2020) (Kg)
Table 67. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Type (2015-2020) (Kg)
Table 71. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Application (2015-2020) (Kg)
Table 73. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Application (2015-2020)
Table 74. GlaxoSmithKline Corporation Information
Table 75. GlaxoSmithKline Description and Major Businesses
Table 76. GlaxoSmithKline CINV Existing and Pipeline Drugs Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 77. GlaxoSmithKline Product
Table 78. GlaxoSmithKline Recent Development
Table 79. Helsinn Corporation Information
Table 80. Helsinn Description and Major Businesses
Table 81. Helsinn CINV Existing and Pipeline Drugs Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 82. Helsinn Product
Table 83. Helsinn Recent Development
Table 84. Heron Therapeutics Corporation Information
Table 85. Heron Therapeutics Description and Major Businesses
Table 86. Heron Therapeutics CINV Existing and Pipeline Drugs Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 87. Heron Therapeutics Product
Table 88. Heron Therapeutics Recent Development
Table 89. Merck Corporation Information
Table 90. Merck Description and Major Businesses
Table 91. Merck CINV Existing and Pipeline Drugs Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 92. Merck Product
Table 93. Merck Recent Development
Table 94. Tesaro Corporation Information
Table 95. Tesaro Description and Major Businesses
Table 96. Tesaro CINV Existing and Pipeline Drugs Production (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2015-2020)
Table 97. Tesaro Product
Table 98. Tesaro Recent Development
Table 99. Global CINV Existing and Pipeline Drugs Sales Forecast by Regions (2021-2026) (Kg)
Table 100. Global CINV Existing and Pipeline Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 101. Global CINV Existing and Pipeline Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 102. Global CINV Existing and Pipeline Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 103. North America: CINV Existing and Pipeline Drugs Sales Forecast by Country (2021-2026) (Kg)
Table 104. North America: CINV Existing and Pipeline Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Europe: CINV Existing and Pipeline Drugs Sales Forecast by Country (2021-2026) (Kg)
Table 106. Europe: CINV Existing and Pipeline Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Asia Pacific: CINV Existing and Pipeline Drugs Sales Forecast by Region (2021-2026) (Kg)
Table 108. Asia Pacific: CINV Existing and Pipeline Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 109. Latin America: CINV Existing and Pipeline Drugs Sales Forecast by Country (2021-2026) (Kg)
Table 110. Latin America: CINV Existing and Pipeline Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Middle East and Africa: CINV Existing and Pipeline Drugs Sales Forecast by Country (2021-2026) (Kg)
Table 112. Middle East and Africa: CINV Existing and Pipeline Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 113. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 114. Key Challenges
Table 115. Market Risks
Table 116. Main Points Interviewed from Key CINV Existing and Pipeline Drugs Players
Table 117. CINV Existing and Pipeline Drugs Customers List
Table 118. CINV Existing and Pipeline Drugs Distributors List
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. CINV Existing and Pipeline Drugs Product Picture
Figure 2. Global CINV Existing and Pipeline Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Aloxi (palonosetron) Product Picture
Figure 4. Zofran Generic (ondansetron) Product Picture
Figure 5. Kytril Generic (granisetron) Product Picture
Figure 6. Emend (aprepitant) Product Picture
Figure 7. Akynzeo (netupitant-palonosetron) Product Picture
Figure 8. SUSTOL (extended release granisetron injection) Product Picture
Figure 9. Rolapitant Product Picture
Figure 10. Global CINV Existing and Pipeline Drugs Sales Market Share by Application in 2020 & 2026
Figure 11. Hospitals
Figure 12. Specialty Clinics
Figure 13. Diagnostic Centers Therapeutics
Figure 14. Hospital Pharmacies
Figure 15. Drugstores
Figure 16. CINV Existing and Pipeline Drugs Report Years Considered
Figure 17. Global CINV Existing and Pipeline Drugs Market Size 2015-2026 (US$ Million)
Figure 18. Global CINV Existing and Pipeline Drugs Sales 2015-2026 (Kg)
Figure 19. Global CINV Existing and Pipeline Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 20. Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2015-2020)
Figure 21. Global CINV Existing and Pipeline Drugs Sales Market Share by Region in 2019
Figure 22. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2015-2020)
Figure 23. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region in 2019
Figure 24. Global CINV Existing and Pipeline Drugs Sales Share by Manufacturer in 2019
Figure 25. The Top 10 and 5 Players Market Share by CINV Existing and Pipeline Drugs Revenue in 2019
Figure 26. CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 27. Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2015-2020)
Figure 28. Global CINV Existing and Pipeline Drugs Sales Market Share by Type in 2019
Figure 29. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2015-2020)
Figure 30. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type in 2019
Figure 31. Global CINV Existing and Pipeline Drugs Market Share by Price Range (2015-2020)
Figure 32. Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2015-2020)
Figure 33. Global CINV Existing and Pipeline Drugs Sales Market Share by Application in 2019
Figure 34. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2015-2020)
Figure 35. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application in 2019
Figure 36. North America CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg)
Figure 37. North America CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 38. North America CINV Existing and Pipeline Drugs Sales Market Share by Country in 2019
Figure 39. North America CINV Existing and Pipeline Drugs Revenue Market Share by Country in 2019
Figure 40. U.S. CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 41. U.S. CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. Canada CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 43. Canada CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. North America CINV Existing and Pipeline Drugs Market Share by Type in 2019
Figure 45. North America CINV Existing and Pipeline Drugs Market Share by Application in 2019
Figure 46. Europe CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg)
Figure 47. Europe CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 48. Europe CINV Existing and Pipeline Drugs Sales Market Share by Country in 2019
Figure 49. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Country in 2019
Figure 50. Germany CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 51. Germany CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. France CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 53. France CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. U.K. CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 55. U.K. CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Italy CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 57. Italy CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Russia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 59. Russia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Europe CINV Existing and Pipeline Drugs Market Share by Type in 2019
Figure 61. Europe CINV Existing and Pipeline Drugs Market Share by Application in 2019
Figure 62. Asia Pacific CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg)
Figure 63. Asia Pacific CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 64. Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Region in 2019
Figure 65. Asia Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Region in 2019
Figure 66. China CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 67. China CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Japan CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 69. Japan CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. South Korea CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 71. South Korea CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. India CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 73. India CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Australia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 75. Australia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Taiwan CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 77. Taiwan CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Indonesia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 79. Indonesia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Thailand CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 81. Thailand CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Malaysia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 83. Malaysia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Philippines CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 85. Philippines CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Vietnam CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 87. Vietnam CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Asia Pacific CINV Existing and Pipeline Drugs Market Share by Type in 2019
Figure 89. Asia Pacific CINV Existing and Pipeline Drugs Market Share by Application in 2019
Figure 90. Latin America CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg)
Figure 91. Latin America CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 92. Latin America CINV Existing and Pipeline Drugs Sales Market Share by Country in 2019
Figure 93. Latin America CINV Existing and Pipeline Drugs Revenue Market Share by Country in 2019
Figure 94. Mexico CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 95. Mexico CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Brazil CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 97. Brazil CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Argentina CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 99. Argentina CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Latin America CINV Existing and Pipeline Drugs Market Share by Type in 2019
Figure 101. Latin America CINV Existing and Pipeline Drugs Market Share by Application in 2019
Figure 102. Middle East and Africa CINV Existing and Pipeline Drugs Sales Growth Rate 2015-2020 (Kg)
Figure 103. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 104. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Country in 2019
Figure 105. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Country in 2019
Figure 106. Turkey CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 107. Turkey CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Saudi Arabia CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 109. Saudi Arabia CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. U.A.E CINV Existing and Pipeline Drugs Sales Growth Rate (2015-2020) (Kg)
Figure 111. U.A.E CINV Existing and Pipeline Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 112. Middle East and Africa CINV Existing and Pipeline Drugs Market Share by Type in 2019
Figure 113. Middle East and Africa CINV Existing and Pipeline Drugs Market Share by Application in 2019
Figure 114. North America CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 115. North America CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Europe CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 117. Europe CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Asia Pacific CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 119. Asia Pacific CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Latin America CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 121. Latin America CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Middle East and Africa CINV Existing and Pipeline Drugs Sales Growth Rate Forecast (2021-2026) (Kg)
Figure 123. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Porter's Five Forces Analysis
Figure 125. Channels of Distribution
Figure 126. Distributors Profiles
Figure 127. Bottom-up and Top-down Approaches for This Report
Figure 128. Data Triangulation
Figure 129. Key Executives Interviewed
化学療法誘発性悪心・嘔吐（CINV）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Chemotherapy Induced Nausea and Vomiting （CINV） Drugs Market The global Chemotherapy Induced Nausea and Vomiting （CINV） Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Chemoth…- ウイルス性結膜炎パイプライン薬剤の世界市場（～2026年） Market Analysis and Insights: Global Viral Conjunctivitis Pipeline Drugs Market The global Viral Conjunctivitis Pipeline Drugs market size is projected to reach US$ 51 million by 2026, from US$ 36 million in 2020, at a CAGR of 39.5%% during 2021-2026. Global Viral Conjunctivitis Pipeline Drugs Scope…
- ネツピタント-パロノセトロンFDCの世界市場（～2026年） The netupitant-palonosetron FDC is an oral therapy that targets two critical pathways associated with acute and delayed CINV by blockage of P/NK1 receptors. Netupitant in the central nervous system inhibits the binding of endogenous tachykinin neuropeptide substance, which prevents chemotherapy-indu…
- 化学療法誘発性悪心・嘔吐（CINV）の世界市場（～2026年） Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides…
- 吸入・点鼻薬ジェネリック医薬品の世界市場（～2026年） Inhalation and Nasal Spray is a kind of drug used to relieve sneezing, runny, stuffy, or itchy nose and itchy, watery eyes caused by hay fever or other allergies. Quality control could pose an issue in the overall growth of generic inhalers and nasal spray sales, an issue that governments are trying…